interleukin-2

(redirected from Aldesleukin)
Also found in: Medical, Encyclopedia.
Related to Aldesleukin: Proleukin

in·ter·leu·kin-2

 (ĭn′tər-lo͞o′kĭn-to͞o′)
n.
A cytokine that is released by T cells in response to an antigen and regulates the proliferation and differentiation of natural killer cells, B cells, and other T cells. It has been used experimentally to treat cancer.
References in periodicals archive ?
UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) has signed an agreement with Swiss drugmaker Novartis to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) for up to USD 210m in cash, consisting of an upfront and deferred payments along with future sales related milestones, the company said.
19 February 2019 - UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) has signed an agreement with Swiss drugmaker Novartis to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) for up to USD 210m in cash, consisting of an upfront and deferred payments along with future sales related milestones, the company said.
United Kingdom-based Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Switzerland-based Novartis, it was reported yesterday.
From the literature review, a roster of 42 reports of SJS (n = 23), SJS/TEN (n = 4), or TEN (n = 15), associated with 12 targeted anticancer drugs, were identified, including EGFR inhibitors (afatinib, cetuximab, erlotinib, gefitinib, panitumumab, and vandetanib), MKI (imatinib, regorafenib, and sorafenib), recombinant IL-2 (aldesleukin), proteasome (bortezomib), anti-CD20 (rituximab), anti-CD30 (brentuximab vedotin), and BRAF inhibitor (vemurafenib) (Table 2).
Like monoclonal antibodies, non-specific immunotherapies or cytokine therapy such as interferons - interferon alpha (Roferon-A [2a], Intron A [2b], Alferon [2a]) and interleukins - interleukin-2, IL-2, or aldesleukin (Proleukin) also help the immune system destroy cancer cells.
Study participants received four treatment cycles each, with daily subcutaneous injections of recombinant human IL-2 (aldesleukin) at single doses of 0.75, 1.5, or 3.0 million IU on 5 consecutive days.